A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer
Cancer Immunology, Immunotherapy · 11.03.2026 · 75 (4)
DOI: 10.1007/s00262-026-04338-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 11.03.2026. Verfasst von Weihong Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Biotherapy, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody therapy has been approved as second-line treatment for advanced non-small-cell lung cancer (NSCLC). Unfortunately, the objective response rate (ORR) is not satisfied. T lymphocytes obtained by co-culture with personalized tumor-specific antigenic peptide-pulsed dendritic cells (DC), also known as multiple target cytotoxic T lymphocytes (MCTL) can restore the antitumor immunity and potentially improve clinical outcomes. We conducted a clinical study evaluating MCTL immunotherapy combined with toripalimab in patients with advanced NSCLC.
Methods
This single-center, open-label, phase Ib trial (NCT04193098) evaluated the combination of MCTL and toripalimab as second-line therapy in 21 patients with advanced NSCLC. Peripheral blood samples were collected for antigenic peptide analysis, and patient immune status was assessed. The primary and secondary endpoints were to evaluate safety and clinical outcomes, respectively.
Results
Among the 21 patients, the ORR and disease control rate (DCR) were 33.3 and 76.2%, respectively. Median overall survival (mOS) was 24.1 months, and median progression-free survival (mPFS) was 8.6 months. Most patients demonstrated improved immune status post-treatment compared to baseline. Patients exhibiting pronounced immune enhancement following MCTL/toripalimab therapy tended to have better clinical outcomes. No significant adverse events (AEs) were observed during combination therapy.
Conclusion
In this cohort of patients with advanced NSCLC, MCTL/toripalimab therapy demonstrated manageable safety and promising antitumor efficacy as a second-line treatment. Further studies are warranted to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Biotherapy, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Can…
- Hebei Bio-High Technology Development Co., Ltd., Shijiazhuang, Hebei, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Qin, J., Luo, J., Xiong, Y., Yang, F., Li, B., Shen, M., Geng, H., Li, Z., Tian, X., Li, S., Li, R., Wang, Y., Zhang, X., Ren, X., Sun, Q., Zhou, L., & Liu, L. (2026). A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 75(4). https://doi.org/10.1007/s00262-026-04338-7
Vancouver
Zhang W, Qin J, Luo J, Xiong Y, Yang F, Li B, et al. A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy. 2026;75(4). doi:10.1007/s00262-026-04338-7
BibTeX
@article{Zhang2026,
author = {Zhang, Weihong and Qin, Jing and Luo, Jing and Xiong, Yanjuan and Yang, Fan and Li, Bin and Shen, Meng and Geng, Huizhen and Li, Zibo and Tian, Xiao and Li, Shuzhan and Li, Runmei and Wang, Yang and Zhang, Xinwei and Ren, Xiubao and Sun, Qian and Zhou, Li and Liu, Liang},
title = {A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {4},
doi = {10.1007/s00262-026-04338-7}
}
EUVIMED